Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells

Oncogene

Volumn 32, Issue 35, 2013, Pages 4130-4138

  Shi, X B ^a   Xue, L ^a   Ma, A H ^a   Tepper, C G ^a   Gandour Edwards, R ^a   Kung, H J ^a   Devere White, R W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

androgen; androgen receptor; miRNA; prostate cancer; tumor suppressor

Indexed keywords

ANDROGEN RECEPTOR; DNA; METRIBOLONE; MICRORNA 124; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICRORNAS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883489767     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.425     Document Type: Article

References (54)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2012; 61: 212-236.
2. Sadar MD. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res 2011; 71: 1208-1213.
3. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
4. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
5. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
6. Shi XB, Tepper CG, White RW. MicroRNAs and prostate cancer. J Cell Mol Med 2008; 12: 1456-1465.
7. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor Cancer Metastasis Rev 2009; 28: 369-378.
8. Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 2007; 27: 435-448.
9. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-776.
10. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer 2009; 124: 2367-2374.
11. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-1429.
12. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31: 766-776.
13. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009; 69: 4443-4453.
14. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 2007; 282: 19575-19588.
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
16. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104: 19983-19988.
17. Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG et al. MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat Struct Mol Biol 2008; 15: 259-267.
18. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23: 862-876.
19. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011; 71: 538-549.
20. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62: 6606-6614.
21. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55: 5195-5199.
22. Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson Jr HF et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 1999; 59: 2329-2331.
23. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202: 233-240.
24. Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 2004; 205: 181-188.
25. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010; 127: 1363-1372.
26. Mazar J, Khaitan D, DeBlasio D, Zhong C, Govindarajan SS, Kopanathi S et al. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PloS One 2011; 6: e24922.
27. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 2008; 68: 210-222.
28. Davis BN, Hata A. Regulation of MicroRNA biogenesis: a miRiad of mechanisms. Cell Commun Signal 2009; 7: 18.
29. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 2008; 105: 7269-7274.
30. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
31. Matsuyama H, Pan Y, Yoshihiro S, Kudren D, Naito K, Bergerheim US et al. Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate 2003; 54: 103-111.
32. Perinchery G, Bukurov N, Nakajima K, Chang J, Hooda M, Oh BR et al. Loss of two new loci on chromosome 8 (8p23 and 8q12-13) in human prostate cancer. Int J Oncol 1999; 14: 495-500.
33. Chang BL, Liu W, Sun J, Dimitrov L, Li T, Turner AR et al. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res 2007; 67: 4098-4103.
34. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
35. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-319.
36. Ostling P, Leivonen SK, Aakula A, Kohonen P, Makela R, Hagman Z et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011; 71: 1956-1967.
37. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-13426.
38. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010; 42: 1348-1354.
39. Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM et al. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 1993; 53: 5512-5516.
40. Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res 2002; 62: 647-651.
41. Frasca F, Rustighi A, Malaguarnera R, Altamura S, Vigneri P, Del Sal G et al. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res 2006; 66: 2980-2989.
42. Pierantoni GM, Rinaldo C, Esposito F, Mottolese M, Soddu S, Fusco A. High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ 2006; 13: 1554-1563.
43. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010; 18: 23-38.
44. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 1996; 7: 1571-1578.
45. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate 2006; 66: 1013-1028.
46. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18: 23-38.
47. Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA 2005; 102: 5156-5161.
48. Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, Orgebin-Crist MC et al. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann NY Acad Sci 2005; 1061: 77-93.
49. Cao X, Pfaff SL, Gage FH. A functional study of miR-124 in the developing neural tube. Genes Dev 2007; 21: 531-536.
50. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001; 47: 212-221.
51. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R et al. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004; 60: 257-271.
52. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997; 31: 1-6.
53. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
54. Shi XB, Bodner SM, deVere White RW, Gumerlock PH. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized singlestrand conformational polymorphism (SSCP) assay. Diagn Mol Pathol 1996; 5: 271-278.